SC
PFE icon

Scotia Capital’s Pfizer PFE Stock Holding History

Scotia Capital’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-173,910
Closed -$5.81M – 817
2016
Q2 		$5.81M Buy
+173,910
New +$5.55M 0.12% 129
2016
Q1 		– Sell
-52,700
Closed -$1.61M – 817
2015
Q4 		$1.61M Hold
52,700
– – 0.04% 310
2015
Q3 		$1.57M Buy
+52,700
New +$1.69M 0.04% 304

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Scotia Capital's PFE Position: Q1 2026 in Review

Scotia Capital reduced its Pfizer (PFE) stake by 3.8% in Q1 2026, selling an estimated $1.1M and leaving 1,058,826 shares worth $29.7M. The position accounts for 0.12% of the portfolio, ranked #104.

Scotia Capital first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $126M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Scotia Capital held 1,058,826 shares of Pfizer worth $29.7M as of Q1 2026.
  • Scotia Capital sold 41,315 Pfizer shares in Q1 2026, an estimated $1.1M.
  • Pfizer made up 0.12% of Scotia Capital's portfolio in Q1 2026, its #104 holding.
  • Scotia Capital first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's Pfizer position peaked at $126M in Q4 2021.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.